Truist Financial Issues Positive Forecast for Fresenius Medical Care (NYSE:FMS) Stock Price

Fresenius Medical Care (NYSE:FMS) had its target price boosted by Truist Financial from $23.00 to $25.00 in a report published on Monday morning,Benzinga reports. They currently have a hold rating on the stock.

A number of other equities research analysts also recently issued reports on the company. Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, StockNews.com started coverage on shares of Fresenius Medical Care in a report on Friday. They set a “strong-buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Fresenius Medical Care has a consensus rating of “Hold” and an average target price of $25.30.

Fresenius Medical Care Price Performance

Shares of FMS opened at $22.79 on Monday. The stock’s 50-day moving average price is $22.28 and its two-hundred day moving average price is $20.69. The stock has a market cap of $13.37 billion, a P/E ratio of 18.83, a price-to-earnings-growth ratio of 0.95 and a beta of 0.94. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

Institutional Trading of Fresenius Medical Care

A number of institutional investors have recently bought and sold shares of FMS. Wulff Hansen & CO. lifted its stake in shares of Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the period. Moran Wealth Management LLC lifted its stake in shares of Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after buying an additional 74,621 shares in the last quarter. Quantinno Capital Management LP lifted its position in Fresenius Medical Care by 78.9% in the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after acquiring an additional 48,554 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of Fresenius Medical Care by 60.4% during the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after buying an additional 23,692 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Fresenius Medical Care in the third quarter worth $420,000. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.